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INTRODUCTION
Motor neuron disorders (MNDs) are a heteroge-
neous group of diseases that result from degener-
ation of motor neurons. If both upper and lower
motor neurons (UMNs and LMNs) are affected,
the disease is classiﬁed as amyotrophic lateral scler-
osis (ALS). Primary lateral sclerosis (PLS) and pro-
gressive muscular atrophy (PMA) selectively affect
the UMNs or LMNs, respectively, but are some-
times considered to be incomplete ALS variants
because their phenotype may evolve into typical
ALS over time. Bulbar affection in a UMN disease
would favour a diagnosis of PLS over hereditary
spastic paraplegia (HSP), whereas rapid progression
may separate PMA from adult-onset spinal muscu-
lar atrophy (SMA).
Some SMA-like or even ALS-like phenotypes
have been incorporated into the large category of
sensorimotor axonal neuropathies (Charcot-Marie-
Tooth disease type 2, CMT2),1 although sensory
abnormalities may be subtle in some forms.2
On the other hand, spinal and bulbar muscular
atrophy (Kennedy disease) is classiﬁed as a form of
adult-onset SMA despite prominent sensory abnor-
malities. It has recently been argued that the
current classiﬁcation system of MNDs is unsatisfac-
tory and should be revised to include genetically
and prognostically important categories.3
We have recently identiﬁed a new form of motor
neuron disease in 55 patients from 17 Finnish
families, where distinctive phenotype did not
match any pre-existing neuromuscular disease
category.4–6 Spinal muscular atrophy Jokela type
(SMAJ, OMIM #615048) is characterised by
painful cramps, fasciculations, decreased or absent
tendon reﬂexes, elevated creatine kinase and hand
tremor. The ﬁrst symptoms appear commonly after
age 30–40. Electromyography (EMG) and muscle
biopsy display widespread neurogenic ﬁndings and
a proportion of patients show sensory abnormal-
ities. Muscle weakness and atrophy appear much
later in the disease course, and patients have
remained ambulant for several decades and their
life expectancy is within normal range.4 5 SMAJ is
caused by a dominant CHCHD10 mutation
c.197G>T p.G66V, a founder mutation in the
Finnish population.6 All Finnish patients reported
so far carry the same mutation that is linked to the
same disease-associated haplotype.5–8
Since the original report in 2014,9 dominant
mutations in CHCHD10 have been identiﬁed to
cause a wide range of neurological disorders.
Certain mutations have been reported to cause
distinct phenotypes such as c.176C>T p.S59L
causing frontotemporal dementia (FTD)-ALS with
mitochondrial myopathy,9 c.172G>C p.G58R iso-
lated mitochondrial myopathy10 and c.197G>T p.
G66V SMAJ6 or CMT2.8 However, the pathogen-
icity of most of the reported mutations has
remained uncertain because the segregation has not
been proven and/or functional studies have not
been available.11–16 So far, most CHCHD10 studies
have been concentrated on patients with ALS,
although other phenotypes, such as SMAJ, seem to
be more prevalent among the ascertained
mutations.
Although CHCHD10 is a mitochondrial protein
and other mutations in CHCHD10 have been
reported to be associated with mitochondrial
myopathy, no signiﬁcant mitochondrial muscle
pathology has been detected in patients with
SMAJ.17 However, in a Finnish cohort of 126 fam-
ilies referred with CMT2 diagnosis, 4.8% had the
c.197G>T p.G66V mutation and low levels of
mitochondrial DNA (mtDNA) deletions were sus-
pected in some.8
In this study, we screened several cohorts of
Finnish patients with distinct neurogenic disorders
and one cohort of mitochondrial myopathy in
order to clarify the presence of CHCHD10 muta-
tions as well as their phenotypic manifestations. To
further study the possible mtDNA instability due to
c.197G>T p.G66V mutation, we compared the
amount of mtDNA deletions in 10 patients with
SMAJ to that of 9 patients with other genetically
conﬁrmed MNDs.
METHODS
Patients
Three hundred and thirty six Finnish patients with
distinct neurogenic disorders at our quaternary
referral centre in Finland were selected for sequen-
cing of the CHCHD10 gene. Of the patients
included in the study, 215 had lower motor neuron
syndrome (LMNS) similar to SMAJ, with or
without some sensory abnormalities. Five of these
patients had an initial clinical diagnosis of CMT2
but with atypical features more suggestive of SMAJ,
such as normal compound muscle action potential
(CMAP) values despite widespread neurogenic
abnormalities, or prominent creatine kinase eleva-
tions up to 1800 U/L. Of the other patients, 28 had
HSP, 24 patients had a non-speciﬁed neurogenic
disorder, 14 patients had mitochondrial myopathy
and 55 patients had a diagnosis of ALS according
to the El Escorial criteria with involvement of
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UMN and LMN. Clinical features of the patient cohorts are pre-
sented in table 1.
In the patients with ALS, mutations in SOD1 and FUS as well
as the repeat expansion mutation in C9orf72 had been previ-
ously excluded. For 23 of the patients with ALS, TARDBP had
also been sequenced with normal ﬁndings. For patients with
HSP, 33 known disease genes were screened by a targeted next-
generation sequencing panel prior to this study (as described in
Ylikallio et al18), without causative ﬁndings. The possible family
history of the patients was not clariﬁed before the study. The
studies were approved by local ethical committees and all
samples were obtained with informed consent.
Molecular genetic analyses
Genomic DNA was extracted from venous blood according to
standard procedures. For all patients, we sequenced exon 2 of
CHCHD10 that harbours all pathogenic mutations reported so
far. Additionally, in 103 patients, the rest of the coding region
of the gene was also sequenced. Of these patients, 79 belonged
to the LMNS group, 2 had mitochondrial myopathy, 15 had a
non-speciﬁed neurogenic disorder and 7 had ALS. Primer
sequences of the exons studied were designed to include the
entire exon and exon–intron borders and are available on
request. The regions studied were ampliﬁed by PCR (Thermo
Scientiﬁc Fermentas PCR Master Mix; MBI Fermentas,
Amherst, New York, USA) and directly sequenced using a
Big-Dye Terminator V.3.1 Kit on an ABI3130xl automatic DNA
Genetic Analyzer (Applied Biosystems, Foster City, California,
USA). Sequences were analysed with Sequencher V.5.1 software
(Gene Codes Corporation, Ann Arbor, Michigan, USA). For
patients with HSP, the sequencing was done as described in
Auranen et al.8
MtDNA analysis
For analysis of mtDNA deletions, we selected 10 patients with
previously proven SMAJ and 9 patients with other genetically
deﬁned MNDs. Mitochondrial pathology on a light microscopic
level was minor (1–2% COX-negative ﬁbres) in the patients
with SMAJ and only present in half (5/10) of the muscle biop-
sies. The group of other genetically deﬁned MNDs consisted of
three patients with ALS-FTD caused by C9orf72 repeat expan-
sion mutation (two with minimal mitochondrial pathology, one
without), ﬁve patients with Kennedy disease (two with minimal
mitochondrial pathology, three without) and one patient with
ALS caused by a homozygous c.272A>C p.D91A mutation in
SOD1. The age of patients with SMAJ ranged from 41 to
57 years, whereas the ages of the other patients were from 39 to
62 years.
The DNA was extracted from muscle biopsies according to
standard procedures. MtDNA deletion load was visualised by
long-range PCR as described in Auranen et al.8
RESULTS
Genetic ﬁndings
Heterozygous mutation c.197G>T p.G66V in CHCHD10 was
detected in 23 patients. In two siblings with a cramping disorder
and mitochondrial pathology, heterozygous c.100C>T p.P34S
was detected. Other mutations were not found.
MtDNA analysis
The results of mtDNA deletion analysis are presented in
ﬁgure 1. The amount of deletions in SMAJ samples was very
low and not higher than in the non-SMAJ samples.
Furthermore, no obvious correlation between the amount of
deletions and the ‘minor mitochondrial’ muscle phenotype of
the patients was observed.
Clinical characteristics of the patients with CHCHD10
mutations
Patients carrying the mutation c.197G>T p.G66V had a
slowly progressive, proximal and distal motor neuronopathy
with reduced tendon reﬂexes. Age at onset ranged from 25 to
Table 1 Patient cohorts included in the study
Disorder
Number of
patients Clinical features
LMNS 215 Predominantly lower motor neuron disease,
including patients with atypical CMT2
(SMAJ-like phenotype)
ALS 55 Signs of UMN and LMN involvement
Non-specific
neurogenic
24 Cramp-fasciculation syndrome, no
widespread weakness, neurogenic findings
on EMG and/or muscle biopsy
HSP 28 No signs of LMN involvement
Mitochondrial
myopathy
14 Muscle histology compatible with
mitochondrial disease
ALS, amyotrophic lateral sclerosis; CMT2, Charcot-Marie-Tooth disease type 2; EMG,
electromyography; HSP, hereditary spastic paraplegia; LMN, lower motor neuron;
LMNS, lower motor neuron syndrome; UMN, upper motor neuron.
Figure 1 The results of mtDNA
deletion analysis in patient groups of
four different MNDs. The 8 kb band
represents the undeleted mtDNA.
Smaller bands correspond to deleted
mtDNA molecules. Low levels of
mtDNA deletions were observed in all
MNDs included in the study, meaning
they are not a speciﬁc feature of
SMAJ. mito+=presence of
mitochondrial pathology in muscle
biopsies, mito−=absence of
mitochondrial pathology in muscle
biopsies, age=age of the patient at
muscle biopsy, H2O=non-template
PCR. MND, motor neuron disorder;
mtDNA, mitochondrial DNA; SMAJ,
spinal muscular atrophy Jokela type.
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70 years, although one patient reported having always been
clumsy (P20). In patient P5, the presenting symptom was
reduced distal upper limb function, while in all others, lower
limb symptoms predominated. The eldest patients, P2 and
P3, still retained some ambulation at the ages of 82
and 86 years. Clinical characteristics of the patients are listed
in table 2.
Similar to our previous report,6 many patients had some
reduction in sensory nerve action potential amplitudes (SNAPs),
but this was extremely variable. For example, sural SNAPs were
severely reduced in an otherwise asymptomatic 28-year-old
woman (P12; 4.0 mV and −4.4 SD), while they were normal in
a 79-year-old man (P2; 4.5 mV and −0.5 SD) with a disease dur-
ation of nearly two decades. In one patient (P8), all sensory
amplitudes were severely reduced at the age of 57 (absent sural
SNAPs with median, ulnar and radial SNAPs <1 mV), even
though the clinical phenotype was typical of SMAJ with are-
ﬂexia, muscle cramps in all limbs followed by slowly progressive
weakness. In contrast to the reduced SNAP values in several
patients, CMAP values were nearly always within normal range,
although one patient has low amplitude CMAP values (P8;
<−2SD) in the upper and lower limbs. None of the patients
developed severe foot drop despite very long disease durations
of several decades. Lower limb muscle MRI in six patients
showed fatty degenerative changes in the calves and posterior
thigh muscles. Muscle biopsy obtained in nine patients displayed
chronic neurogenic abnormalities with ﬁbre type grouping and
groups of normal sized type IIA ﬁbres. Three out of 15 patients
(P8, P17, P20) in this cohort showed ﬁbrillations in the ﬁrst
dorsal interosseous muscle, which we previously have also
shown to be very rare in SMAJ, as an important distinction
from ALS.19
Patients carrying c.100C>T p.P34S were siblings who had a
cramping disorder with normal tendon reﬂexes and no neuro-
genic changes on EMG. Muscle biopsy ﬁndings suggested a
mitochondrial myopathy. A third sibling with the same clinical
and muscle pathology phenotype, however, did not carry the
variant. The parents of the siblings were asymptomatic, but
their DNA samples were not available for the study.
DISCUSSION
In our cohort of 336 Finnish patients with undetermined MND
or mitochondrial myopathy, 23 proved to have the Finnish
founder mutation c.197G>T p.G66V in CHCHD10. The
phenotype of all of them was restricted to SMAJ. Previously,
c.197G>T p.G66V mutation carriers have also been identiﬁed
in a Finnish cohort of patients referred by the clinicians as
having CMT2.8 There is growing evidence that dominantly
Table 2 Clinical characteristics of the patients with heterozygous CHCHD10 mutation c.197G>T p.G66V
Patient Sex
Age at
onset Symptoms at onset
Age at
examination Inheritance
Walking
ability
Neurography/electromyography
abnormalities CK
P1 F 30 Cramps 68 AD 1 km Age 68: sensorimotor 2–3×
P2 M 60 Cramps 82 Sporadic Needs a
walker
Age 79: sensorimotor (normal sural but
reduced upper limb SNAPs)
2×
P3 M 70 Fasciculations 86 AD Needs a
walker
Age 82: sensorimotor (normal sural but
reduced upper limb SNAPs)
2–3×
P4 M 25 Cramps 57 AD Normal Age 57: sensorimotor 2–3×
P5 F 46 Weakness 67 AD Normal Age 42: motor
Age 66: sensorimotor
Normal
P6 F Before age
62
Cramps 66 AD Normal Motor ND
P7 M 42 Weakness, fasciculations 44 AD Normal Motor ND
P8 M 40 Weakness 55 AD Normal Sensorimotor 3×
P9 F 25 Cramps 37 AD Normal Motor 1.5×
P10 M 42 Weakness 49 Sporadic Normal Motor ND
P11 F 40 Cramps 60 AD Normal Motor ND
P12 F 28 Asymptomatic with absent
tendon reflexes
52 AD Normal Age 28: sensorimotor
Age 52: very little progression in sensory
findings
ND
P13 M 46 Myalgia 49 AD Normal Age 46: sensorimotor 3–6×
P14 F Before age
42
Cramps 48 AD Normal Age 42: motor 2×
P15 F Before age
60
Cramps 65 AD Normal Sensorimotor 2–3×
P16 F 54 Cramps 55 AD Normal Age 54: motor 1.5×
P17 M 46 Weakness 55 AD Normal Age 53: sensorimotor 2–3×
P18 F 39 Weakness and cramps 59 AD Normal Age 39: motor
Age 49: sensorimotor
2×
P19 F Before age
64
Impaired walking/balance 70 AD Walking
sticks
Age 67: motor ND
P20 F Childhood? Clumsiness in childhood,
could be unrelated
60 AD <1 km Age 60: sensorimotor ND
P21 F 40 Cramps 58 AD Normal Age 58: motor axonal Normal
P22 M 48 Weakness and fasciculations 51 Sporadic Normal Age 51: sensorimotor 1.5–5×
P23 F 58 Weakness 70 AD Walking
sticks
Age 69: Motor axonal 1.5×
AD, autosomal dominant; CK, creatine kinase; F, female; M, male; ND, not detected; SNAP, sensory nerve action potential.
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inherited mutations in other genes that cause SMA may also
cause CMT2. At least mutations in HSPB1, MFN2 and
DYNC1H1 do not cause distinct entities but a continuum of
phenotypes ranging from SMA to CMT2.20–22 As we have
reported previously, SNAP reductions may occur in patients
with SMAJ,5 6 despite almost no clinical evidence of sensory
dysfunction. In our experience, patients with SMAJ typically
show clinical and/or EMG ﬁndings in a proximal and distal dis-
tribution already at the initial investigations, in contrast to
CMT2, where disease progression to proximal muscles is a late
phenomenon. In this respect, SMAJ is more similar to Kennedy
disease (although with absent bulbar signs). Even though
c.197G>T p.G66V has been reported in the literature to cause
ALS,8 23–25 all these reports erroneously reference one family
reported by Müller et al11 as ALS. In fact, this Finnish family
was deﬁned with a motor neuron disease without stated UMN
ﬁndings, and this family was later detailed in our SMAJ cohort
as not having ALS.6 We nevertheless consider SMAJ to be an
important differential diagnostic alternative in patients with a
neurogenic disorder suggestive of CMT2 or ALS, because in
routine clinical practice without highly detailed analysis, patients
with SMAJ have received both of these diagnoses before the
ﬁnal molecular diagnosis.
Two patients, a brother and a sister, carried the variant
c.100C>T p.P34S, but their third similarly affected sibling was
not a carrier. Since the variant c.100C>T p.P34S did not
segregate with the disease in this family, it is not likely to be
disease causing. This is also supported by the reports of Zhang
et al15 and Dobson-Stone et al16 who showed that c.100C>T
p.P34S is present in a normal population with a considerable
frequency.
Mutation c.100C>T p.P34S is one of many CHCHD10
mutations suggested to be pathogenic based on their absence
from international variant databases (table 3). Further evidence
is required, however, because most variants at the 50 end of
CHCHD10 exon 2 are not included in variant databases due
to low coverage of that area in exome sequences.16 As the
quality and number of exome sequences increase, it is probable
that many of the reported CHCHD10 variants appear to have
some kind of frequency in a normal population making their
pathogenic role more unlikely. Out of 11 CHCHD10 variants
reported, at least 4 have received a frequency in the ExAC
database (table 3), after the ﬁrst reports of their possible patho-
genicity. Since the population frequency seems to depend
both on time and the population studied, it is not recommend-
able to call a variant pathogenic based on the population
frequency alone.
Our results suggest that c.197G>T p.G66V is a common
mutation in Finland, with 93 patients reported so far. In the
SISu database V.3.0 (http://www.sisuproject.ﬁ) of 6104 Finnish
individuals, c.197G>T p.G66V has been identiﬁed once. On
the basis of the number of our determined patients and the SISu
frequency, we estimate the prevalence of c.197G>T p.G66V to
be around 2–4/100 000 in Finland. Other mutations in
CHCHD10 are not common, at least not in the Finnish popula-
tion. Our results also provide further evidence that pathogenic
mutations in CHCHD10 are concentrated in exon 2, as previ-
ously reported (see table 3).12 13 27
So far, only three mutations in CHCHD10 have strong evi-
dence for causality. Two of these, c.176C>T p.S59L and
c.172G>C p.G58R, have been associated with mitochondrial
myopathy and mtDNA instability.9 10 CHCHD10 protein is
part of the mitochondrial mitochondrial contact site and cristae
organizing system (MICOS) complex, which is involved in
cristae organisation and thus mtDNA nucleoid maintenance.28
However, the patients carrying c.197G>T p.G66V have not
presented signs of mitochondrial myopathy and mitochondrial
pathology has not been considerable in their muscle biopsies. In
this study, we compared the amount of mtDNA deletions in 10
patients with SMAJ with 9 patients with other genetically
deﬁned MNDs. No signiﬁcant increased amount of mtDNA
deletions could be observed in the patients with SMAJ, support-
ing that mitochondrial pathology is not a feature of the SMAJ
phenotype.
In general, CHCHD10-related disorders seem to be rare world-
wide. So far, only three mutations causing three distinct
Table 3 Reported variants in CHCHD10
Mutation Exon
Frequency
in ExAC
Reported
phenotypes
Number of
reported
patients
Patient
origin
Pathogenic
according to
functional
studies
Segregates
with the
disease References NB
c.34C>T p.P12S 1 0.00001682 ALS 1 Spain NA NA 24
c.43C>A p.R15S* 2 – MM 10 Puerto Rico No Yes 10
c.44C>A p.R15L 2 – ALS 13 Germany,
USA, Canada
NA No/yes 11 13 15 26
c.67C>A p.P23T 2 – FTLD 1 Italy NA NA 15
c.100C>T p.P34S 2 0.0009654 ALS, FTD-ALS,
PD, AD
15 France, Italy,
Canada,
Australia
NA No 12 14–16 27 Indications that the
variant is not
pathogenic15 16
c.104C>A p.A35D 2 – FTLD 1 Italy NA NA 15
c.172G>C p.G58R* 2 – MM 10 Puerto Rico Yes Yes 10
c.176C>T p.S59L 2 – FTD-ALS with
MM
9 France, Spain Yes Yes 9 12
c.197G>T p.G66V 2 – SMAJ, CMT2 73 Finland NA Yes 6 8 11 23
c.239C>T p.P80L 2 0.0003461 ALS 4 Italy, Canada NA Possibly 14 15 Small number of
patients
c.244C>T p.Q82X 2 0.00004243 FTD 1 Spain NA NA 24
The variants have been annotated according to transcript NM_213720.
AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CMT2, Charcot-Marie-Tooth disease type 2; FTD, frontotemporal dementia; FTLD, frontotemporal lobar degeneration; MM,
mitochondrial myopathy; NA, not assessed; PD, Parkinson’s disease; SMAJ, spinal muscular atrophy Jokela type.
*Mutations in cis.
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phenotypes have been reported, with other ﬁndings still requiring
further evaluation (table 3). Of the ascertained CHCHD10-related
disorders, SMAJ is by far the most frequent disease. This is at
least in part due to the enrichment of the founder mutation in the
genetically isolated Finnish population. Genealogical information
of the patients with SMAJ found in this study was clariﬁed retro-
spectively. Patient P3 was found to belong to a family reported by
Pasanen et al23 and patient P12 was related to a family reported
by Penttilä et al.6 Patients P11 and P15 are sisters, as are patients
P19 and P20 (ﬁgure 2A). No relations between other patients
to each other or to the previously known families were found.
However, owing to the founder effect of the c.197G>T p.G66V
mutation in the Finnish population, it is evident that all Finnish
patients carrying the mutation have a common ancestry, probably
of Northern Karelian origin (ﬁgure 2B). The presence of SMAJ in
other populations still needs further studies but, considering the
large numbers of Finnish emigrants to different countries during
the past 150 years, SMAJ should exist in some descendants.
Furthermore, CHCHD10 mutations have mostly been evaluated
in ALS cohorts and it is possible that CHCHD10 mutations are
more prevalent in other disease types. Cohorts of patients with
adult-onset lower MNDs, including Kennedy disease phenocopies,
should be screened for CHCHD10 mutations.
Our results support the hypothesis that CHCHD10 mutations
have a relatively strict genotype–phenotype correlation. However,
more studies in different cohorts are deﬁnitely needed as well as
further functional studies to elucidate how the different mutations
result in the particular phenotypes.
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